quetiapin medical valley forðatafla 200 mg
medical valley invest ab - quetiapinum fúmarat - forðatafla - 200 mg
quetiapin medical valley forðatafla 400 mg
medical valley invest ab - quetiapinum fúmarat - forðatafla - 400 mg
valpress comp filmuhúðuð tafla 160/12,5 mg
teva b.v.* - valsartanum inn; hydrochlorothiazidum inn - filmuhúðuð tafla - 160/12,5 mg
valpress comp filmuhúðuð tafla 80/12,5 mg
teva b.v.* - valsartanum inn; hydrochlorothiazidum inn - filmuhúðuð tafla - 80/12,5 mg
valsartan/hydrochlorothiazide krka filmuhúðuð tafla 160 mg/12,5 mg
krka sverige ab - hydrochlorothiazide; valsartanum inn - filmuhúðuð tafla - 160 mg/12,5 mg
valsartan/hydrochlorothiazide krka filmuhúðuð tafla 160 mg/25 mg
krka sverige ab - hydrochlorothiazide; valsartanum inn - filmuhúðuð tafla - 160 mg/25 mg
valsartan/hydrochlorothiazide krka filmuhúðuð tafla 80 mg/12,5 mg
krka sverige ab - valsartanum inn; hydrochlorothiazide - filmuhúðuð tafla - 80 mg/12,5 mg
pylclari
curium pet france - piflufolastat (18f) - blöðruhálskirtli - greining geislavirkja - Þetta lyf er eingöngu ætlað til greiningar. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).
methotrexate orion pharma (methotrexate orion) tafla 2,5 mg
orion corporation - methotrexatum inn - tafla - 2,5 mg
evrysdi
roche registration gmbh - risdiplam - vöðvaáfall, mænu - Önnur lyf við sjúkdómum í stoðkerfi - evrysdi is indicated for the treatment of 5q spinal muscular atrophy (sma) in patients with a clinical diagnosis of sma type 1, type 2 or type 3 or with one to four smn2 copies.